Now, researchers at Stanford University School of Medicine have shown that by targeting CD47 – better known for its role as an innate immune checkpoint akin to PD-1 and CTLA-4 in the adaptive immune system – they were able to restore muscle stem cell function. Aged mice regained muscle strength comparable to younger animals after receiving an antibody treatment targeting CD47 signaling in muscle stem cells. Read More
Two recent studies have reported new insights into the role of the tumor-associated microbiome in both drug response and metastasis. Researchers working at the Fred Hutchinson Cancer Center, Seattle, reported in the Nov. 16, 2022, issue of Nature that bacteria can promote the spreading of cancer as single cells with recruitment of myeloid host cells. In a parallel publication, the same team reported in the Nov. 15, 2022, issue of Cell Reports that the primary chemotherapy used to treat colorectal cancer (CRC), 5-fluorouracil (5-FU), was less effective when the tumor included bacteria that were insensitive to 5-FU antimicrobial activity. Read More
Nona Biosciences, a wholly owned subsidiary of HBM Holdings Ltd., has entered into a collaboration agreement with Dragonfly Therapeutics Inc. based on Nona's proprietary fully human heavy chain only antibody (HCAb) transgenic mice platform to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation. Read More
Researchers from Cerevel Therapeutics LLC presented data from a study that aimed to evaluate preclinical antipsychotic properties of M4 agonism while minimizing off-target side effects using novel muscarinic acetylcholine M4 receptor full and partial agonists, CV-0000042 (CVL-042) and CV-0000071, respectively. Read More
Researchers from Shasqi Inc. have reported the development of a new monomethyl auristatin E (MMAE)-based therapeutic, SQ-2270, within its proprietary CAPAC (Click Activated Protodrugs Against Cancer) platform for the treatment of cancer. Read More
Medshine Discovery Inc. has disclosed derivatives of a six-membered heteroaromatic urea ring acting as soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of diabetic and hypertensive nephropathy. Read More
Suzhou Suncadia Biopharmaceuticals Co. Ltd. and Jiangsu Hengrui Medicine Co. Ltd. have synthesized isoquinolone compounds acting as phosphodiesterase PDE3A and/or PDE4 inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD), sepsis, nephritis, diabetes, allergic rhinitis, allergic conjunctivitis and rheumatic diseases. Read More
Male infertility affects approximately 20% to 70% of infertile couples mostly due to decreased sperm count, sperm motility and/or morphological abnormalities. Read More
Merck Sharp & Dohme Corp. has identified small-molecule GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Aerie Pharmaceuticals Inc. has divulged dual-acting compounds consisting of a glucocorticoid moiety and a Rho kinase 1 (ROCK) inhibitor bound through a linker. They are reported to be useful for the treatment of eye disorders. Read More
Noncoding RNAs, such as long noncoding RNAs (lncRNAs), are important regulators and markers of cardiovascular diseases. Saphenous veins are frequently used in coronary artery bypass surgery, but about 50% of the saphenous vein grafts fail in the first 10 years after surgery due to neointima formation. Read More
Kotobuki Pharmaceutical Co. Ltd. and Astellas Pharma Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration and inflammatory disorders. Read More
